PILL:NYE-Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF (USD)

ETF | Trading--Leveraged Equity |

Last Closing

USD 7.04

Change

-0.24 (-3.30)%

Market Cap

N/A

Volume

0.20M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-14 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B..

+0.27 (+0.97%)

USD 9.17B
QLD ProShares Ultra QQQ

-0.25 (-0.24%)

USD 7.84B
FNGU MicroSectors FANG+ Index 3X Le..

-6.00 (-1.09%)

USD 7.31B
SSO ProShares Ultra S&P500

+0.22 (+0.24%)

USD 5.60B
UPRO ProShares UltraPro S&P500

+0.25 (+0.29%)

USD 4.27B
TECL Direxion Daily Technology Bull..

+0.68 (+0.81%)

USD 3.10B
YINN Direxion Daily FTSE China Bull..

+1.59 (+6.80%)

USD 1.32B
USD ProShares Ultra Semiconductors

-0.53 (-0.83%)

USD 1.16B
UDOW ProShares UltraPro Dow30

+1.38 (+1.49%)

USD 0.91B
LABU Direxion Daily S&P Biotech Bul..

-7.17 (-8.29%)

USD 0.82B

ETFs Containing PILL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.85% 54% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.85% 54% F 39% F
Trailing 12 Months  
Capital Gain -10.66% 14% F 16% F
Dividend Return 0.99% 44% F 13% F
Total Return -9.67% 12% F 15% F
Trailing 5 Years  
Capital Gain -75.56% 17% F 5% F
Dividend Return 0.97% 16% F 3% F
Total Return -74.59% 17% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain 57.69% 79% B- 94% A
Dividend Return 58.25% 79% B- 94% A
Total Return 0.56% 41% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 392.92% 15% F 3% F
Risk Adjusted Return 14.82% 27% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.